Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Tao, Leilei ^a   Huang, Guichun ^a   Shi, Shujing ^a   Chen, Longbang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Adoptive CIK cells therapy; Antiangiogenesis; Bevacizumab; Hypoxia microenvironment; Vascular normalization

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL HOMING; CELL THERAPY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; INTRAVENOUS ADMINISTRATION; LUNG NON SMALL CELL CANCER; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CYTOLOGY; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; MONONUCLEAR CELL; PHENOTYPE; TUMOR CELL LINE;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; FEMALE; HUMANS; HYPOXIA; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PHENOTYPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84887876497     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0777-3     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi: 10.3322/caac.21166.
2. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363-8.
3. Luo H, Zhou X. Researche advances on CIK cells and their clinical use in lung cancer. Chin J Lung Cancer. 2011;14(12):954-9. doi: 10.3779/j.issn.1009- 3419.2011.12.10.
4. Draghiciu O, Nijman HW, Daemen T. From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol. 2011;2011:439053. doi: 10.1155/2011/439053.
5. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109(43):17561-6. doi: 10.1073/pnas.1215397109.
6. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol. 2012;3:21. doi: 10.3389/fimmu.2012.00021.
7. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 2010;136(8):1201-11. doi: 10.1007/s00432-010-0770-6.
8. Myers AL, Williams RF, Ng CY, Hartwich JE, Davidoff AM. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg. 2010;45(6):1080-5. doi: 10.1016/j.jpedsurg.2010.02.068.
9. Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH, et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res. 2012;18(12):3328-39. doi: 10.1158/1078-0432.CCR-11- 3000.
10. Jz J. The additive of drug combination. Acta Pharm Sinica. 1980;1(1):70-3.
11. Shi S, Wang R, Chen Y, Song H, Chen L, Huang G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS ONE. 2013;8(6):e65757. doi: 10.1371/journal.pone.0065757.
12. Linn YC, Yong HX, Niam M, Lim TJ, Chu S, Choong A, et al. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012;14(7):851-9. doi: 10.3109/14653249.2012.694419.
13. Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18(6):1751-9. doi: 10.1158/1078-0432.CCR-11- 2442.
14. Huang X, Chen YT, Song HZ, Huang GC, Chen LB. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol. 2011;17(25):3002-11. doi: 10.3748/wjg.v17.i25.3002.
15. Berraondo P, Umansky V, Melero I. Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res. 2012;72(20):5159-64. doi: 10.1158/0008-5472.CAN-12-1952.
16. Huang X, Huang G, Song H, Chen L. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model. Int J Cancer. 2011;129(3):648-58. doi: 10.1002/ijc.25702.
17. Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol. 2012;227(4):417-30. doi: 10.1002/path.4053.
18. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486. doi: 10.1101/cshperspect.a006486.
19. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2-3):72-84. doi: 10.1016/j.mvr.2007.05.003. (Pubitemid 350051025)
20. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J Control Release. 2012;164(3):265-75. doi: 10.1016/j.jconrel.2012.07.013.
21. Young RJ, Moller A. Immunohistochemical detection of tumour hypoxia. Methods Mol Biol. 2010;611:151-9. doi: 10.1007/978-1-60327-345-9-12.